{"id":"NCT02436096","sponsor":"Tonix Pharmaceuticals, Inc.","briefTitle":"A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia","officialTitle":"A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04","primaryCompletion":"2016-09","completion":"2016-09","firstPosted":"2015-05-06","resultsPosted":"2025-02-07","lastUpdate":"2025-02-07"},"enrollment":519,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia","Myofascial Pain Syndromes","Muscular Diseases","Musculoskeletal Diseases","Nervous System Diseases","Neuromuscular Diseases","Rheumatic Diseases"],"interventions":[{"type":"DRUG","name":"TNX-102 SL Tablet, 2.8mg","otherNames":["Low dose cyclobenzaprine sublingual tablets"]},{"type":"DRUG","name":"Placebo SL Tablet","otherNames":["Placebo sublingual tablets"]}],"arms":[{"label":"TNX-102 SL Tablet, 2.8 mg","type":"EXPERIMENTAL"},{"label":"Placebo SL Tablet","type":"PLACEBO_COMPARATOR"}],"summary":"The use of low-dose CBP dosed nightly at bedtime for FM was supported by the results of Tonix' TNX-CY-F202 Phase 2b study (also referred to as the BESTFIT Study). The TNX-CY-F202 study provided evidence that TNX-102 SL 2.8 mg dosed nightly results in beneficial effects upon pain, sleep and other FM symptomatology.\n\nThe present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.","primaryOutcome":{"measure":"Proportion of Patients With â‰¥30% Pain Improvement","timeFrame":"Day 1, Week 12","effectByArm":[{"arm":"Placebo SL Tablet","deltaMin":58,"sd":null},{"arm":"TNX-102 SL Tablet, 2.8 mg","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":256},"commonTop":["Hypoaesthesia Oral","Glossodynia","Paraesthesia Oral","Fatigue","Product Taste Abnormal"]}}